Business Context and Reporting Period
This Form 8-K reports on the Annual Meeting of Stockholders held by Revolution Medicines, Inc. on June 22, 2021. The company is incorporated in Delaware and its common stock trades on the Nasdaq Global Select Market under the symbol RVMD. As of the record date (April 23, 2021), there were 73,442,606 shares of common stock outstanding and entitled to vote.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance matters and stockholder voting results.
Material Changes and Voting Results
Stockholders voted on two proposals at the Annual Meeting:
- Proposal 1: Election of Class I Directors
- Elizabeth McKee Anderson: 48,734,154 votes For; 5,990,116 votes Withheld; 3,955,561 Broker Non-Votes.
- Neil Exter: 48,666,825 votes For; 6,057,445 votes Withheld; 3,955,561 Broker Non-Votes.
- Flavia Borellini, Ph.D.: 54,689,926 votes For; 34,344 votes Withheld; 3,955,561 Broker Non-Votes.
- Proposal 2: Ratification of Independent Auditor
- PricewaterhouseCoopers LLP was ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2021.
- Votes For: 58,666,814
- Votes Against: 4,416
- Abstentions: 8,601
- No broker non-votes were recorded for this proposal.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document serves solely to disclose the results of the stockholder vote.
Key Facts for Investor Verification
- Verify the successful election of the three Class I director nominees (Anderson, Exter, and Borellini) to serve until the 2024 annual meeting.
- Confirm the ratification of PricewaterhouseCoopers LLP as the independent auditor for the 2021 fiscal year.
- Note the significant number of broker non-votes (3,955,561) recorded for the director election proposal.
- Review the definitive proxy statement on Schedule 14A filed on April 28, 2021, for detailed background on the proposals.